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SUMMARY
Laboratory, Borstel, Germany
SETTING: After the collapse of the Soviet Union, coun-
tries in the region faced a dramatic increase in tubercu-
losis cases and the emergence of drug resistance.
OBJECTIVE: To discuss the relevance of the DOTS strat-
egy in settings with a high prevalence of drug resistance.
DESIGN: Retrospective analysis of one-year treatment
outcomes of short-course chemotherapy (SCC) and re-
sults of drug susceptibility testing (DST) surveys of six
programmes located in the former Soviet Union: Ke-
merovo prison, Russia; Abkhasia, Georgia; Nagorno-
Karabagh, Azerbaijan; Karakalpakstan, Uzbekistan;
Dashoguz Velayat, Turkmenistan; and South Kazakh-
stan Oblast, Kazakhstan. Results are reported for new
and previously treated smear-positive patients.
RESULTS: Treatment outcomes of 3090 patients and
DST results of 1383 patients were collected. Treatment
success rates ranged between 87% and 61%, in Nagorno-
Karabagh and Kemerovo, respectively, and failure rates
between 7% and 23%. Any drug resistance ranged be-
tween 66% and 31% in the same programmes. MDR
rates ranged between 28% in Karakalpakstan and
Kemerovo prison and 4% in Nagorno-Karabagh.
CONCLUSION: These results show the limits of SCC in
settings with a high prevalence of drug resistance. They
demonstrate that adapting treatment according to resis-
tance patterns, access to reliable culture, DST and good
quality second-line drugs are necessary.
KEY WORDS: tuberculosis; treatment outcomes; drug
resistance; Eastern Europe
AFTER THE COLLAPSE of the Soviet Union, most
countries in the region faced a dramatic increase in
tuberculosis (TB) incidence.1 The collapse of na-
tional TB programmes (NTPs) induced drug short-
ages, unreliable drug quality, over-the-counter med-
icines and poor treatment adherence. Facing what
could be considered an epidemic, the World Health
Organization (WHO) and the international commu-
nity pushed the NTPs to implement the DOTS strat-
egy. The approach of the NTPs was until then based
on case detection and follow-up by radiography,
long course individual chemotherapy and massive
use of primary and secondary prophylaxis,2 and pol-
icy makers were reluctant to accept a new strategy.
After a pilot phase supported by international or-
ganisations, they slowly accepted DOTS.3 However,
unexpectedly high failure rates rapidly indicated po-
tentially high levels of drug resistance. Previous drug
resistance surveys conducted in DOTS pilot projects
in Russia, the Baltic countries and Georgia showed
rates of initial multidrug resistance (MDR) of be-
tween 9% and 20%.4 No data were available for
other countries in the former Soviet Union (FSU).
Drug resistance is a major obstacle for NTPs to
reach the WHO goal of 85% cure rate among new
infectious TB cases.
The aim of the present study is to report new re-
sults on TB drug resistance and treatment outcomes
from programmes in Russia, Uzbekistan, Turkmeni-
stan, Kazakhstan, Georgia and Azerbaijan, and to
discuss the limits of DOTS in settings with a high
prevalence of drug resistance.
STUDY POPULATION AND METHODS
Setting
The non-governmental organisation Médecins Sans
Frontières (MSF) supported six programmes in the
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FSU region. The ﬁrst programme started in 1996 in
Kemerovo Oblast, Russia, covering a population of
30000 prisoners. Between 1998 and 2000, three
projects started in Central Asia in the civilian popula-
tion: in the semiautonomous Republic of Karakal-
pakstan, Uzbekistan (1.5 million); in Dashoguz Ve-
layat, Turkmenistan (1.2 million), and in two districts
of South Kazakhstan Oblast, Kazakhstan (140000).
Another two programmes were implemented in the
autonomous regions of Nagorno-Karabagh, Azer-
baijan (100000) and Abkhasia, Georgia (250000),
in 1997 and 1999, both in a context of long-term
conﬂict.
Intervention
Diagnosis and treatment followed WHO and Interna-
tional Union Against Tuberculosis and Lung Disease
(IUATLD) recommendations.5 Case detection was
passive for civilians and active for prisoners. Diagno-
sis was mainly based on sputum microscopy after
Ziehl-Neelsen staining and on ﬂuorescence micros-
copy in prison. New cases (NCs) were deﬁned as pa-
tients who had never had treatment for TB or who
had taken anti-tuberculosis drugs for  1 month. Pre-
viously treated cases (PTCs) were deﬁned as patients
who had previously received anti-tuberculosis drugs
for a month or more. Patients were treated by stan-
dard short-course chemotherapy (SCC): NCs re-
ceived a 6-month regimen, with 2 months of isoniazid
(H, INH), rifampicin (R, RMP), ethambutol (E, EMB)
and pyrazinamide (Z), followed by 4 months of HR
(2HREZ/4HR); PTCs were given an 8-month regimen,
with 2 months of streptomycin (S, SM) and HRZE, 1
month of HRZE, followed by 5 months of HRE
(2SHRZE/1HRZE/5HRE). On the basis of prelimi-
nary results of drug susceptibility testing (DST), SM
was not used for PTCs in Kemerovo. Treatment was
given daily at the in-patient facility during the inten-
sive phase, and three times a week in ambulatory
health posts during the continuation phase. In prisons,
treatment was given daily for the whole duration.
Health care workers directly supervised drug intake
in all projects. Since May 1999 in Nagorno-Karabagh
and July 2001 in Abkhasia, patients with drug-resistant
TB have been given adapted treatment including
second-line drugs according to their individual
DST results.6–8
Treatment follow-up was based on sputum micros-
copy. In prisons, supervision of sputum collection and
drug intake were very strict to avoid cheating (spit-
ting out drugs or sputum exchange between patients)
by prisoners wanting to remain in the TB department
where living conditions were better. Anti-tuberculosis
drugs of guaranteed quality were provided by MSF.
Quality control of the laboratories in each programme
was performed on randomised samples of slides on a
quarterly basis. TB notiﬁcation rates were calculated
in each programme by dividing the number of TB
cases diagnosed by the population covered and ex-
pressed per 100000 population.
Analysis of standard SCC outcomes
Deﬁnitions of treatment outcomes followed WHO/
IUATLD recommendations: 1) cured: patient present-
ing a negative sputum smear in the last month of
treatment and on at least one previous occasion; 2)
failure: patient presenting a positive smear at 5 months
or later during treatment; 3) death: patient who died
from any reason during the course of treatment; 4)
defaulted: patient who interrupted treatment for 2 or
more consecutive months; 5) transfer out: patient
transferred to another DOTS unit and for whom
treatment outcome was not known; 6) treatment com-
pleted: patient who completed treatment but did not
meet the criteria for cured or failure; 7) treatment suc-
cess: patients declared either cured or treatment com-
pleted.9 In Kemerovo prison, patients released before
treatment completion were considered as defaulters,
as no DOTS-based programme was in place in the
civilian society during the study period.
Rates of different treatment outcomes were calcu-
lated by the ratio of the number of patients with one
outcome divided by the total of patients enrolled in
the programme for the period of the analysis. Treat-
ment outcomes of all smear-positive patients treated
with SCC in each programme were collected. Drug-
resistant patients who received a treatment regimen
adjusted to their DST during the study period were
excluded from the analysis of the SCC. Results for
2001 were compiled for each programme for NCs
and PTCs separately. Because of the small size of the
programme, the results were compiled for 2 years
(1999 and 2000) in Nagorno-Karabagh. Standard SCC
outcomes were analysed according to the DST results
for 2001 in Abkhasia and Kemerovo prison. In Ke-
merovo prison, culture was performed for patients
who had fully susceptible strains on admission and
were classiﬁed as failures at 5 months.
DST SURVEY
Each project conducted a DST survey, except for the
programme in South Kazakhstan Oblast. Results from
a survey performed in another region of Kazakhstan
(Almaty region) are presented. Conventional cultures
were performed on solid Lowenstein-Jensen media
and DST for ﬁrst-line drugs was based on the propor-
tion method, with SM 8  g/ml, INH 0.2  g/ml, RMP
40.0  g/ml and EMB 5.0  g/ml.10
Consecutive positive sputum samples were col-
lected at each diagnostic centre. Samples were sent di-
rectly to a Supranational Reference Laboratory (SRL):
the National Mycobacterial Reference Laboratory,
Borstel, Germany, for Karakalpakstan and Dashoguz
Velayat; Istituto Superiore Di Sanita, Rome, Italy, for
Abkhasia; and Institute of Tropical Medicine (ITM),DST and treatment outcomes in FSU 1149
Antwerp, Belgium, for Nagorno-Karabagh and Almaty
region. In Kemerovo prison, DST was performed lo-
cally in a laboratory supported by MSF and super-
vised by the ITM.
Results were collected separately for NCs and
PTCs. ‘Any resistance’ was deﬁned as resistance to at
least one TB drug, monoresistance as resistance to
only one drug, polydrug resistance (PDR) as resis-
tance to more than one drug and MDR as resistance
to at least INH and RMP.4 The periods of surveys
differed according to the stage and size of the project:
2001 in Kemerovo prison, July 2001 to January
2002 in Karakalpakstan and Dashoguz Velayat,
September 2000 to August 2002 in Abkhasia, May
1997 to December 1998 in Almaty region and May
1999 to December 2002 in Nagorno-Karabagh.
The proportions of different resistance proﬁles were
calculated.
Statistical analyses
Univariate analysis was performed using Epi Info ver-
sion 6.04d (Centers for Disease Control, Atlanta, GA,
2001). In Abkhasia and Kemorovo prison, negative
outcomes were deﬁned as the association of failures,
defaulters and died, and positive outcomes as treat-
ment success. Transferred patients were excluded from
the analysis. Positive and negative outcomes were ex-
amined in groups of patients presenting a strain with
‘any resistance,’ MDR and monoresistance to INH
(or INH   SM) and compared with those with fully
susceptible strains. Crude odds ratios (OR) and 95%
conﬁdence intervals (CI) were used for the interpreta-
tion of univariate analysis. Fisher’s exact test was used
when the expected value of a cell was  5. P values
 0.05 were considered signiﬁcant.
RESULTS
TB case notiﬁcation rates per 100 000 were 4600
in Kemerovo prison, 200 in Karakalpakstan, 100 in
Dashoguz Velayat, 150 in Abkhasia, 86 in Nagorno-
Karabagh and 250 in South Kazakhstan Oblast.
In Abkhazia and Nagorno-Karabagh, respectively
17 and 9 patients were excluded from analysis of the
SCC outcome as their treatment was adjusted to indi-
vidual DST. Standard SCC outcomes of 3088 smear-
positive cases, including 1377 NCs and 1711 PTCs,
are presented in Tables 1 and 2. Overall, SCC treat-
ment success rates ranged between 87% in Nagorno-
Karabagh and 63% in Siberia. Failure rates ranged
between 23% in Kemerovo prison and 7% in Nagorno-
Karabagh. Death rates ranged between 11% in Ka-
rakalpakstan and 2% in Nagorno-Karabagh.
Results of DST surveys are reported in Table 3 for
a total of 1383 patients. The proportions of patients
with TB resistant to INH were 54% in Kemerovo
prison, 53% in Karakalpakstan, 31% in Dashoguz
Velayat, 37% in Abkhasia, 28% in Nagorno-Kara-
bagh and 59% in Almaty region. MDR rates ranged
between 28% in Karakalpakstan and Kemerovo
prison and 4% in Nagorno-Karabagh.
Treatment outcomes according to DST results are
presented for 459 patients in Kemerovo prison and
163 patients in Abkhasia, in Tables 4 and 5. In
Abkhasia, a negative outcome was observed in 60%
of the ‘any resistance’ group, 95% of MDR, 46% of
Table 1 Treatment outcomes of new cases for the Siberia, Uzbekistan, Turkmenistan, Abkhasia and Kazakhstan programmes
for 2001 and for the Nagorno-Karabagh programme for 1999 and 2000
n
Cured 
n (%)
Treatment 
completed 
n (%)
Treatment 
success
n (%)
Died
n (%)
Failure
n (%)
Defaulted 
n (%)
Transferred
n (%)
Kemerovo prison 452 303 (67) 17 (3.8) 320 (70.8) 8 (1.8) 75 (16.6) 49 (10.8) 0
Karakalpakstan 396 183 (46.2) 86 (21.7) 269 (67.9) 21 (5.3) 64 (16.2) 35 (8.8) 7 (1.8)
Dashoguz Velayat 306 193 (63.1) 56 (18.3) 249 (81.4) 7 (2.3) 26 (8.5) 24 (7.8) 2 (0.1)
Abkhasia 76 38 (50) 28 (36.5) 66 (86.8) 2 (2.6) 2 (2.6) 5 (6.5) 1 (1.3)
Karabagh 57 28 (49) 25 (44) 53 (93) 1 (2) 1 (2) 2 (3.5) 0
South Kazakhstan Oblast 90 57 (63) 11 (12) 68 (76) 4 (4) 13 (14) 2 (2) 3 (3)
Table 2 Treatment outcomes of previously treated cases for the Siberia, Uzbekistan, Turkmenistan, Abkhasia and Kazakhstan 
programmes for 2001 and for the Nagorno-Karabagh programme for 1999 and 2000
n
Cured
n (%)
Treatment 
completed
n (%)
Treatment
success
n (%)
Died
n (%)
Failure
n (%)
Defaulted
n (%)
Transferred
n (%)
Kemerovo prison 304 155 (51) 4 (1.3) 159 (52.3) 11 (3.6) 96 (31.6) 38 (12.5) 0
Karakalpakstan 645 253 (39.2) 104 (16.1) 257 (55.3) 90 (14) 98 (15.2) 91 (14.1) 9 (1.4)
Dashoguz Velayat 505 285 (56.4) 68 (13.5) 353 (69.9) 37 (12.1) 38 (12.4) 70 (13.9) 7 (1.3)
Abkhasia 112 39 (34.8) 26 (23.2) 65 (58) 9 (8) 8 (7.1) 26 (23.2) 4 (3.5)
Karabagh 30 18 (60) 5 (17) 23 (77) 1 (3) 5 (17) 1 (3) 0
South Kazakhstan Oblast 115 51 (44) 13 (11) 64 (56) 14 (12) 22 (19) 7 (6) 8 (7)1150 The International Journal of Tuberculosis and Lung Disease
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patients resistant to INH (or INH   SM) and 21% in
the group with fully susceptible TB. In Kemerovo
prison, it was respectively 42%, 59%, 57% and 22%.
In Kemerovo prison, culture and DST were available
for 15 of 16 patients with fully susceptible strains on
admission classiﬁed as failures: 9 were conﬁrmed by
culture, 8 had MDR strains and 6 had a negative cul-
ture. The risk of a negative outcome was signiﬁcantly
higher in patients with drug-resistant TB than in pa-
tients with fully susceptible TB in Abkhasia (OR 5.7;
95%CI 2.7–12.1, P   0.01) and in Kemerovo prison
(OR 2.6; 95%CI 1.6–4.2, P   0.01). Resistance to
INH or INH   SM was signiﬁcantly associated with
negative outcomes in both programmes (OR 3.1;
95%CI 1.2–7.8, P   0.01 and OR 5.3; 95%CI 3.1–
9.2, P   0.01). MDR was strongly associated with
negative outcomes in both programmes (OR 77.4;
95%CI 9.8–1664.3, P   0.01 and OR 5.3; 95%CI
3.1–9.2, P   0.01).
DISCUSSION
These programmes had a similar history and back-
ground of TB control, although the size and type of
their target population, the level of implementation
(district or regional) and the geopolitical contexts
were different. The SCC outcomes in Nagorno-Kara-
bagh and Kemerovo prison were similar to those re-
ported at national level in Azerbaijan and Russia in
2000 (91% and 68% success rates for NCs and 3%
and 13% failure rates, respectively).4 In Karakalpak-
stan, Kemerovo prison and South Kazakhstan Oblast,
Table 5 Treatment outcomes by DST results for the Kemerovo prison programme for 2001
n
Cured 
n (%)
Treatment 
completed
n (%)
Treatment
success
n (%)
Died 
n (%)
Failure 
n (%)
Defaulted
n (%)
Fully susceptible 157 92 (58.6) 31 (19.7) 123 (78.3) 2 (1.3) 16 (10.2) 16 (10.2)
Any resistance 302 115 (38.1) 60 (19.9) 175 (57.9) 11 (3.6) 98 (32.4) 18 (6)
MDR 128 31 (24.2) 21 (16.4) 52 (40.6) 9 (7) 58 (45.3) 9 (7)
HR 1 0 0 0 0 1 0
HRS 35 8 (22.5) 7 (20) 15 (42.9) 2 (5.7) 17 (48.6) 1 (2.9)
HRE 1 0 1 1 0 0 0
HRES 91 23 (25.3) 13 (14.3) 36 (39.6) 7 (7.7) 40 (44) 8 (8.8)
RS 0 0 0 0 0 0 0
RES 1 0 0 0 0 1 0
HE 3 1 1 2 0 1 0
HS 66 30 (45.5) 11 (16.8) 41 (65.1) 1 (1.5) 20 (30.3) 4 (6.1)
ES 8 4 2 6 0 2 0
HES 33 12 (36.4) 11 (33.3) 23 (69.7) 0 7 (21.2) 3 (9.1)
H 19 9 (47.4) 4 (21.1) 13 (68) 1 (5.3) 4 (21.1) 1 (5.3)
R 1 1 0 10 00
E 6 2 3 50 10
S 37 25 (67.6) 7 (18.9) 32 (86.5) 0 4 (10.8) 1 (2.7)
DST   drug susceptibility testing; MDR   multidrug resistance; H   isoniazid; R   rifampicin; S   streptomycin; E   ethambutol.
Table 4 Treatment outcomes by DST results for the Abkhasia programme for 2001
n
Cured 
n (%)
Treatment
completed
n (%)
Treatment
success 
n (%)
Died
n (%)
Failure 
n (%)
Defaulted
n (%)
Transferred 
n (%)
Fully susceptible 91 47 (51.6) 23 (25.3) 70 (76.9) 6 (6.6) 1 (1.1) 12 (13.2) 2 (2.2)
Any resistance 72 18 (25) 10 (13.9) 28 (38.9) 4 (5.5) 21 (29.2) 18 (25) 1 (1.3)
MDR  22 1 (4.5) 0 1 (4.5) 3 (13.6) 10 (45.4) 8 (36.4) 0
HR 1 0 0 0 0 0 1 0
HRS 5 1 0 0 0 3 1 0
HRE 0 0 0 0 0 0 0 0
HRES 16 0 0 0 3 (18.7) 7 (43.7) 6 (37.5) 0
RS 0 0 0 0 0 0 0 0
RES 0 0 0 0 0 0 0 0
HE 1 0 0 0 0 1 0 0
HS 12 4 (33.3) 2 (16.7) 6 (50) 0 4 (25) 2 (16.7) 0
ES 0 0 0 0 0 0 0 0
HES 4 1 0 1 1 2 0 0
H 23 9 (39.1) 4 (17.4) 13 (56.5) 0 4 (17.4) 6 (26.1) 0
R2 0 1 1 0 0 1 0
E0 0 0 0 0 0 0 0
S 8 3 3 6 0 0 1 1
DST   drug susceptibility testing; MDR   multidrug resistance; H   isoniazid; R   rifampicin; S   streptomycin; E   ethambutol.1152 The International Journal of Tuberculosis and Lung Disease
treatment outcomes were sub-optimal, with success
rates for NCs far below the DOTS objective of 85%.6
The high defaulter rate in Kemerovo prison was ex-
plained by the amnesty and release of patients before
treatment completion and by the absence of a DOTS
unit in the civilian community during the study pe-
riod. The exclusion of patients with drug-resistant TB
who received adapted treatment regimens in Ab-
khasia and Nagorno-Karabagh may have resulted in
an overestimation of the treatment success rate and an
underestimation of the failure and death rates.
The DST surveys conﬁrm the importance of drug
resistance, as suspected from the poor treatment out-
comes. In Karakalpakstan and Almaty region, the MDR
rates were equivalent to those reported in Latvia and
Estonia, with 9% and 14% of MDR among NCs.11
Coninx et al. reported similar results in an Azerbaijan
prison to those in Kemerovo prison, with 27% of MDR
among NCs.12 Drug resistance was higher for INH
and SM, which were prescribed intensively during the
Soviet period for TB and other infectious diseases.3
The failure rate observed in Kemerovo prison in
patients with fully susceptible strains was surprisingly
high. Although occasional cheating cannot be totally
excluded, the quality of the implementation of the
programme can hardly explain these results, as all
procedures were strictly supervised. Forty per cent of
the failures (6/15) as deﬁned by smear microscopy
were not conﬁrmed as such by culture. This could be
explained by the presence of dead bacilli at 5 months
in patients with large cavities. The high proportion of
MDR (89%) among the failures conﬁrmed by culture
suggests that a more probable explanation was re-
infection by more resistant strains in the TB wards.13
Conﬁrmation of this hypothesis would require DNA
ﬁngerprinting.14,15 Some authors have reported mixed
infection with different Mycobacterium tuberculosis
strains that could explain inconsistent DST results.15–17
We found a signiﬁcant association between drug
resistance and unfavourable outcomes. MDR is known
as an independent risk factor of treatment failure and
death.15,18–23 In Kemerovo prison, the 7% death rate
observed in patients with MDR-TB was surprisingly
low compared to the overall death rate (5%). The
proportion of chronic cases among patients with
MDR-TB and the impact of the systematic supply of
high-energy food on treatment outcomes should be
investigated. The success rate for patients with MDR-
TB under SCC was low, as previously reported.15,24–26
It was probably overestimated in our study, as treat-
ment outcomes were deﬁned by direct microscopy
only.7,27 A high recurrence rate would have been
expected but could not be measured, as follow-up
after treatment completion was not systematically re-
corded. A previous study in Russia reported 27%
recurrence among patients with MDR-TB considered
cured under SCC.24 According to our study, adminis-
tering a 6-month regimen to any NC would result in
RMP monotherapy during the continuation phase for
20–50% of patients, resulting in an increased risk of
resistance to RMP.21,28 Adding SM to the PTC treat-
ment regimen was ineffective in one third to two thirds
of cases. INH prophylaxis would have been inappro-
priate for contact cases of 25–50% of the patients.
These results underline the need for more DST sur-
veys to better understand anti-tuberculosis drug resis-
tance in FSU.29,30 They also highlight the need for cul-
ture for patient follow-up rather than relying only on
sputum microscopy.31 In settings where there is a high
prevalence of drug resistance, adapting treatment ac-
cording to DST results is necessary. Both standard
and individual MDR treatment strategies have been
proposed in different settings.8,32 Considering the fre-
quency of other forms of resistance (H, HS, HE) and
the fact that some second-line drugs (mainly ethiona-
mide and kanamycin) were widely used during the
Soviet period, individually adapted treatment is prob-
ably advisable in this region. This was initiated during
the study period and progressively implemented in
Nagorno-Karabagh and Abkhazia, and has been used
since 2003 in Karakalpastan. To date about 300 pa-
tients with drug-resistant TB have received adapted
treatment in these programmes.
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RÉSUMÉ
CONTEXTE: Après l’effondrement de l’URSS, les pays de
la région ont déploré une augmentation importante des
cas de tuberculose et de l’émergence de la résistance aux
antituberculeux.
OBJECTIFS: Discuter la pertinence de la stratégie DOTS
dans les régions avec une haute prévalence de résistance.
SCHÉMA : Analyse rétrospective des résultats de la chi-
miothérapie à courte durée (SCC) pendant un an et des
enquêtes de résistance dans six programmes en ex-URSS :
Kemerovo prison (Russie), Abkhasie (Géorgie), Nagorno-
Karabagh (Azerbaïdjan), Karakalpakstan (Ouzbékistan),
Dashoguz-Velayat (Turkmenistan) et South Kazakh-
stan Oblast (Kazakhstan). Les résultats sont reportés
pour les patients à frottis positif nouveaux et déjà
traités.
RÉSULTATS: Les résultats de traitement de 3090 pa-
tients et les proﬁls de résistance de 1383 patients ont été
collectés. Les taux de succès variaient entre 87% au
Nagorno-Karabagh et 61% à Kemerovo et les taux
d’échec entre 7% et 23%. Entre 66% des patients à Ke-
merovo et 31% au Nagorno-Karabagh étaient résistants
à au moins un antituberculeux. Entre 28% au Karakal-
pakstan et à Kemerovo et 4% au Nagorno-Karabagh
étaient multirésistants.
CONCLUSION: Ces résultats montrent les limites du SCC
dans les régions à haute prévalence de résistance aux
antituberculeux. L’adaptation thérapeutique en fonction
de la résistance, l’utilisation de la culture plus antibio-
gramme et l’accès à des antituberculeux de 2nde ligne de
bonne qualité sont nécessaires.1154 The International Journal of Tuberculosis and Lung Disease
RESUMEN
MARCO DE REFERENCIA: Después del colapso de la
Unión Soviética, los países de la región confrontan un
grave aumento de los casos de tuberculosis y la aparición
de resistencia a los medicamentos.
OBJETIVO: Analizar la pertinencia de la estrategia
DOTS en ambientes con alta prevalencia de resistencia a
los medicamentos antituberculosos.
MÉTODO: Análisis retrospectivo del desenlace del trata-
miento de un año, con el protocolo acortado (SCC) y de
los resultados de estudios de sensibilidad a los medica-
mentos, de seis programas ubicados en la antigua Unión
Soviética  : la prisión de Kemerovo (Rusia), Abkhasia
(Georgia), Nagorno-Karabagh (Azerbaiján), Karakalpak-
stán (Uzbekistán), Dashoguz Velayat (Turkmenistán) y
Oblast Kazajstán del sur (Kazajstán). Los resultados del
tratamiento de casos con baciloscopia positiva se agru-
pan por pacientes nuevos y pacientes con antecedente de
tratamiento previo.
RESULTADOS: Se estudió el desenlace del tratamiento
de 3090 pacientes y el resultado de 1383 pruebas de sen-
sibilidad a los medicamentos. Las tasas de tratamiento
exitoso oscilaron entre el 87% en Nagorno-Karabagh y
el 61% en Kemerovo, y las tasas de fracaso entre el 7% y
el 23%. En estos mismos programas, se encontró algún
tipo de resistencia a los medicamentos en el 66% y el 31%
de los casos, respectivamente. Se observaron tasas de
multidrogorresistencia entre el 28% en Karakalpakstán y
la prisión de Kemerovo y el 4% en Nagorno-Karabagh.
CONCLUSIÓN: Los resultados pusieron en evidencia los
límites del SCC en ambientes con alta prevalencia de re-
sistencia a los medicamentos. Demostraron también la
necesidad de adaptar el tratamiento al tipo de resistencia
y de tener acceso a un cultivo ﬁable, a las pruebas de sen-
sibilidad y a medicamentos de segunda línea de buena
calidad.